BR112014023415A2 - moléculas que se ligam a ang2 - Google Patents

moléculas que se ligam a ang2

Info

Publication number
BR112014023415A2
BR112014023415A2 BR112014023415A BR112014023415A BR112014023415A2 BR 112014023415 A2 BR112014023415 A2 BR 112014023415A2 BR 112014023415 A BR112014023415 A BR 112014023415A BR 112014023415 A BR112014023415 A BR 112014023415A BR 112014023415 A2 BR112014023415 A2 BR 112014023415A2
Authority
BR
Brazil
Prior art keywords
ang2
binding molecules
molecules
bind
binding
Prior art date
Application number
BR112014023415A
Other languages
English (en)
Other versions
BR112014023415B1 (pt
Inventor
Gschwind Andreas
Borges Eric
Depla Erik
Stevenaert Frederik
Boucneau Joachim
Buyse Marie-Ange
Merchiers Pascal
Georg Ott Rene
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014023415(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112014023415A2 publication Critical patent/BR112014023415A2/pt
Publication of BR112014023415B1 publication Critical patent/BR112014023415B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo patente de invenção: "moléculas que se ligam a ang2". a presente invenção refere-se a moléculas que se ligam a ang2, preferivelmente domínios variáveis únicos de imunoglobulina que se ligam a ang2 como vhhs e domínios de anticorpo, composições farmacêuticas que contenham as mesmas e seu uso no tratamento de doenças que são associadas a efeitos mediados por ang2 sobre a angiogênese. ácidos nucleicos que codificam as moléculas que se ligam a ang2, células hospedeiras e métodos para prepará-las. 1/100
BR112014023415-9A 2012-03-30 2013-03-27 Molécula que se liga a ang2, seu método para produção e seu uso, célula hospedeira e composição farmacêutica BR112014023415B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162615.4 2012-03-30
EP12162615 2012-03-30
PCT/EP2013/056635 WO2013144266A1 (en) 2012-03-30 2013-03-27 Ang2-binding molecules

Publications (2)

Publication Number Publication Date
BR112014023415A2 true BR112014023415A2 (pt) 2017-07-11
BR112014023415B1 BR112014023415B1 (pt) 2022-04-12

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023415-9A BR112014023415B1 (pt) 2012-03-30 2013-03-27 Molécula que se liga a ang2, seu método para produção e seu uso, célula hospedeira e composição farmacêutica

Country Status (27)

Country Link
US (5) US20130259859A1 (pt)
EP (1) EP2831111B1 (pt)
JP (1) JP5970734B2 (pt)
KR (1) KR102020255B1 (pt)
CN (1) CN104321344B (pt)
AU (1) AU2013241769B2 (pt)
BR (1) BR112014023415B1 (pt)
CA (1) CA2865464C (pt)
CL (1) CL2014002393A1 (pt)
CY (1) CY1122007T1 (pt)
DK (1) DK2831111T3 (pt)
EA (1) EA031182B1 (pt)
ES (1) ES2729165T3 (pt)
HR (1) HRP20190817T1 (pt)
HU (1) HUE044263T2 (pt)
IL (1) IL234234B (pt)
IN (1) IN2014DN06904A (pt)
LT (1) LT2831111T (pt)
MX (1) MX350248B (pt)
NZ (1) NZ628584A (pt)
PH (1) PH12014502179A1 (pt)
PL (1) PL2831111T3 (pt)
PT (1) PT2831111T (pt)
RS (1) RS58732B1 (pt)
SI (1) SI2831111T1 (pt)
TR (1) TR201908638T4 (pt)
WO (1) WO2013144266A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US20170233467A1 (en) 2014-10-17 2017-08-17 Amgen Inc. Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
IL254589B2 (en) * 2015-03-31 2023-11-01 Vhsquared Ltd A peptide structure with a protease-cleavable linker
PL3328886T3 (pl) 2015-07-29 2021-02-08 Allergan, Inc. Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu
US20190300967A1 (en) * 2016-10-13 2019-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
MX2019014199A (es) * 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
WO2020006511A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
WO2021178209A1 (en) * 2020-03-03 2021-09-10 Aptitude Medical Systems, Inc. Aptamers and use thereof
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
US20240279324A1 (en) 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists
AU2021463580A1 (en) * 2021-09-10 2024-04-11 Soter Biopharma Pte. Ltd. Anti-ang2 antibody, preparation method therefor, and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT656946E (pt) 1992-08-21 2001-12-28 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
IL156955A0 (en) 2001-01-17 2004-02-08 Genecraft Inc Binding domain-immunoglobulin fusion proteins
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
CA2595610C (en) 2004-12-21 2013-03-05 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
AR061245A1 (es) 2006-06-06 2008-08-13 Genentech Inc Composiciones y metodos para la modulacion del desarrollo vascular
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2009221106A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009147248A2 (en) * 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2364328A2 (en) * 2008-12-10 2011-09-14 Ablynx NV Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2

Also Published As

Publication number Publication date
PT2831111T (pt) 2019-05-31
MX2014011171A (es) 2015-03-06
KR20140146606A (ko) 2014-12-26
EA031182B1 (ru) 2018-11-30
TR201908638T4 (tr) 2019-07-22
KR102020255B1 (ko) 2019-09-10
PL2831111T3 (pl) 2019-09-30
DK2831111T3 (en) 2019-04-29
PH12014502179B1 (en) 2014-12-10
LT2831111T (lt) 2019-05-10
CN104321344A (zh) 2015-01-28
CN104321344B (zh) 2017-11-21
AU2013241769A1 (en) 2014-08-28
US20170107281A1 (en) 2017-04-20
US20130259859A1 (en) 2013-10-03
JP5970734B2 (ja) 2016-08-17
RS58732B1 (sr) 2019-06-28
PH12014502179A1 (en) 2014-12-10
CL2014002393A1 (es) 2015-01-23
CA2865464C (en) 2022-07-12
HRP20190817T1 (hr) 2019-06-28
JP2015516805A (ja) 2015-06-18
CA2865464A1 (en) 2013-10-03
HUE044263T2 (hu) 2019-10-28
EP2831111A1 (en) 2015-02-04
US20230203146A1 (en) 2023-06-29
SI2831111T1 (sl) 2019-06-28
EA201401065A1 (ru) 2015-03-31
WO2013144266A1 (en) 2013-10-03
BR112014023415B1 (pt) 2022-04-12
NZ628584A (en) 2016-04-29
US20200207845A1 (en) 2020-07-02
CY1122007T1 (el) 2020-10-14
IL234234B (en) 2020-06-30
ES2729165T3 (es) 2019-10-30
EP2831111B1 (en) 2019-03-20
US20190135907A1 (en) 2019-05-09
IN2014DN06904A (pt) 2015-05-15
AU2013241769B2 (en) 2017-05-11
MX350248B (es) 2017-08-31

Similar Documents

Publication Publication Date Title
BR112014023415A2 (pt) moléculas que se ligam a ang2
BR112013025304A2 (pt) moléculas de ligação biespecíficas que ligam a vegf e ang2
BR112012007294A2 (pt) moléculas de ligação a dll4
UY33588A (es) Moleculas de union a vegf
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
BR112014011594A2 (pt) anticorpos anti-il-36r
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
PE20160528A1 (es) Anticuerpos
EA201591898A1 (ru) Антитела, направленные на m-csf
BR112014027372A2 (pt) anticorpos anti-il-23p19
BR112014021080A2 (pt) polipeptídeos de ligação de cx3cr1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2013, OBSERVADAS AS CONDICOES LEGAIS.